Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Neurology. Clinical practice·2026

Same author

Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.

European journal of neurology·2026

Same author

Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study.

Journal of neurology·2026

Same author

Caution in interpreting disease-modification claims with lecanemab: Selective reporting and causal inference.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

Thymic health under the microscope.

Nature·2026

Same author

Looking Beyond Dose: Identifying Responders and Non-Responders to RehaCom Computerized Cognitive Rehabilitation in Progressive MS-The CogEx Study.

Neurorehabilitation and neural repair·2026

Search research articles

Related Experiment Video

Updated: May 15, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Biomarker development for myasthenia gravis.

Henry J Kaminski¹, Linda L Kusner, Gil I Wolfe

¹Neurology Pharmacology and Physiology, George Washington University, Washington, DC, USA. HKaminski@mfa.gwu.edu

Annals of the New York Academy of Sciences

|January 3, 2013

Summary

Biomarker discovery in myasthenia gravis (MG) aims to find reliable indicators of treatment effectiveness. New technologies and the MGTX trial are advancing this crucial area of clinical research.

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

Related Experiment Videos

Last Updated: May 15, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

Area of Science:

Biomedical research
Clinical trial methodology
Biomarker discovery

Background:

Biomarkers objectively measure disease processes or treatment responses.
Current myasthenia gravis (MG) biomarkers aid diagnosis but not treatment response prediction.
Emerging technologies facilitate comprehensive biomarker discovery in biological fluids.

Purpose of the Study:

To identify novel biomarkers for myasthenia gravis (MG).
To find reliable substitutes for clinical endpoints in MG clinical trials.
To advance the understanding of MG pathogenesis and treatment efficacy.

Main Methods:

Utilizing longitudinal data and biospecimens from the MGTX trial.
Performing RNA and protein analysis on plasma and serum samples.
Analyzing thymus tissue for biomarker discovery.

Main Results:

The MGTX trial provides a robust platform for biomarker discovery.
New technologies enable broad analysis of biological fluids for potential biomarkers.
Existing MG biomarkers are insufficient for predicting treatment response.

Conclusions:

Biomarker evaluation is best performed within longitudinal clinical trials.
The MGTX trial is poised to yield significant advancements in MG biomarker discovery.
The ultimate goal is to find biomarkers that directly measure therapeutic effectiveness and patient well-being.